Endoscopic profile and clinical outcome of patients presenting with upper gastrointestinal bleeding

Ashish Kumar, Umang Kasturi, Amritpal Singh*, Dharamjit Kaur

Department of Medicine, Government Medical College Patiala, Punjab, India

Received: 19 May 2020
Revised: 13 July 2020
Accepted: 18 July 2020

*Correspondence:
Dr. Amritpal Singh,
E-mail: dr.apsingh10@gmail.co.in

ABSTRACT

Background: Acute upper gastrointestinal bleeding is a common medical emergency with significant mortality. The aim of the present study is to study endoscopic profile and clinical outcome of patients presenting with upper gastrointestinal bleeding in this region.

Methods: This prospective observational study carried out on 100 patients admitted with upper gastrointestinal bleeding. All patients included in study underwent upper gastrointestinal endoscopy after initial evaluation and stabilization. Status of study group patients was noted at discharge. Patients were telephonically contacted at day 15 and were asked about rebleed, readmission for gastrointestinal bleed or death of the patient.

Results: The mean age of patients was 48.98 ±14.50 years with male to female ratio of 2.57:1. The most common lesions causing UGI bleed were related to portal hypertension (esophageal and gastric varices) and were seen in 67% of patients. Non portal hypertensive lesions causing UGI bleed (peptic and other lesions) were seen in 46% patients. Twenty six percent patients had combination of lesions while endoscopy was normal in 3% patients. Rebleeding within 15 days was seen in 11 patients out of whom 3 died during same admission. Out of other 8 patients with rebleed, readmission was seen in 6 patients while 2 patients had minor bleed. We found no correlation of mortality and rebleed with factors like age, history of liver disease, diabetes, NSAIDs use, peptic ulcer disease and presence of cirrhosis. However the correlation between rebleed and death was found to be statistically significant.

Conclusions: Portal hypertension is the most common cause of upper gastrointestinal bleeding in this region. There is strong correlation between rebleeding and death. However there is no correlation between age, history of liver disease, diabetes, NSAIDs use, peptic ulcer disease and presence of cirrhosis with rebleed or mortality.

Keywords: Causes of upper gastrointestinal bleed, cirrhosis, Duodenal ulcer, Gastric ulcer, Gastrointestinal bleeding

INTRODUCTION

Upper gastrointestinal bleeding refers to blood loss within the intraluminal gastrointestinal tract from any location between the upper esophagus to the duodenum at the level of the ligament of Treitz.1 It is a common medical emergency associated with significant morbidity and mortality. The overall incidence of acute upper gastrointestinal hemorrhage has been estimated at 50 to 100 per 100,000 patients per year, with an annual hospitalization rate of approximately 100 per 100,000 hospital admissions.2,3 Causes of UGI bleed have been classified to variceal (e.g. esophageal and gastric varices) and non-variceal (e.g. peptic ulcer, erosive gastroduodenitis, reflux esophagitis, tumor, vascular ectasias, etc.).4 Helicobacter pylori (H. pylori) infection and the use of nonsteroidal antiinflammatory drugs (NSAIDs) are two of the major risk factors for peptic
ulcers and ulcer complications. Variceal bleed is the major cause of upper gastrointestinal bleeding in cirrhotic patients, accounting for 70% of cases. Mortality during the first episode is estimated to 15-20%, but is higher in severe patients (Child Pugh C), at around 30%, whereas it is very low in patients with compensated cirrhosis (Child Pugh A). The main predictors of bleeding in clinical practice are: large versus small varices, red wale marks, Child Pugh C versus Child Pugh A–B. The primary diagnostic test for evaluation of UGI bleed is endoscopy. Early endoscopy and endoscopic appearance of certain lesions helps to guide care and thereby reduce the costs and duration of hospitalization. At present, there is a paucity of data on endoscopic profile and clinical outcome of patients of UGI bleed from this region. Therefore, this study was planned with an aim to identify clinical and endoscopic profile of patients admitted with UGI bleed and to determine their clinical outcome.

**METHODS**

This observational prospective study was carried out on patients admitted with UGI bleed. Study was conducted over 9 months from August 2018 to May 2019 and included 100 patients presenting with upper gastrointestinal bleed. Written and informed consent was taken from every patient. Clearance was taken from ethical committee of our institute before undertaking this study. The study included patients aged 18 and above who were admitted with complaint of UGI bleed. Patients who were unfit for upper gastrointestinal endoscopy (UGIE) such as in or unconscious patients were excluded from the study. Patients were subjected to upper gastrointestinal endoscopy and endoscopic findings (and therapeutic procedure if any) were noted down. Status of all patients who underwent upper gastrointestinal endoscopy in this study was noted at the time of discharge/death. Patients were telephonically contacted 15 days after discharge and were asked about rebleed, readmission for gastrointestinal bleed or death of patient. Collected data was analyzed using statistical methods such as mean, median, standard deviation (SD) per value and Chi-square test/ Fisher’s exact test. The results were displayed in tables with categorical variables presented as numbers and percentages, and the continuous variables presented as mean ± SD.

**RESULTS**

The study comprised of 100 patients presenting with UGI bleed during the study period. The mean age in the study population was 48.98 ±14.50 years and the male to female ratio was 2.57:1 (M: 72, F: 28). Epidemiological and clinical profile of patients is shown in Table 1.

In this study most common lesions causing UGI bleed were related to portal hypertension (esophageal varices, gastric varices) and were seen in 67% of patients (Figure 1). In patients with variceal UGI bleed, esophageal varices were seen in 62% cases, gastric varices in 2%, esophageal + gastric varices in 3%, PGH + esophageal varices in 18% and PHG alone in 3% patients. Non portal hypertensive lesions causing UGI bleed were seen in 46% patients and various lesions noted on endoscopy are shown Figure 1. Twenty six patients had more than one kind of lesions on endoscopy as shown in Table 2.

**Table 1: Epidemiological and clinical profile of patients.**

| Clinical parameter | Number of patients | Percentage of patients |
|--------------------|--------------------|------------------------|
| Males              | 72                 | 72.0                   |
| Females            | 28                 | 28.0                   |
| Hematemesis        | 79                 | 79.0                   |
| Melena             | 81                 | 81.0                   |
| Hematemesis and melena | 60     | 60.0                   |
| Regular alcohol intake | 49             | 49.0                   |
| Tobacco smoking and chewing | 22       | 22.0                   |
| NSAIDs use         | 14                 | 14.0                   |
| History of liver disease | 54       | 54.0                   |
| History of variceal ligation | 19     | 19.0                   |

**Figure 1: The endoscopic diagnosis of patients with UGI bleed.**

In 3% patients UGIE was normal. In this study, 65 patients underwent endoscopic variceal ligation (EVL) of esophageal varices and 5 patients were injected with cyanoacrylate glue into the gastric varices. Out of the total of 23 patients with ulcer related bleed, 9 patients underwent endotheraphy (adrenaline injection) and rest of
the lesions did not warrant any endoscopic intervention. One patient with duodenal ulcer needed surgical intervention due to failure of endotherapy. The endoscopic diagnosis of patients with UGI bleed cases are shown in Figure 1.

Table 2: Various combinations of lesions in seen in single patients

| Lesions                                      | Count (%) |
|----------------------------------------------|-----------|
| Varices + PHG                                | 14 (14.0) |
| Varices + peptic ulcer                       | 3 (3.0)   |
| Varices + erosions                           | 1 (1.0)   |
| Varices + PHG + peptic ulcer                 | 2 (2.0)   |
| Varices + PHG + erosions                     | 2 (2.0)   |
| Varices + peptic ulcer + erosions            | 1 (1.0)   |
| Gastric ulcer + erosions                     | 3         |
| Duodenal ulcer + erosions                    | 1         |
| Gastric ulcer + stomach cancer               | 1         |
| PHG + erosions                               | 2         |
| PHG + duodenal ulcer + erosions              | 1         |

Figure 2: Clinical outcome of patients with UGI bleed.

In the present study, 11 (11%) patients rebled within 15 days of the initial presentation. Out of those 11 patients with rebleeding, 3 (3%) patients died and all the deaths happened during same hospital stay (Figure 2). Eight patients had rebleeding after the discharge and out of them 6 got readmitted while 2 patients had minor bleed not warranting readmission.

Table 3: Age distribution of mortality and rebleed.

| Age (in years) | Death | Rebleed |
|----------------|-------|---------|
| 8-20           | 0     | 1.0%    |
| 21-30          | 0     | 3.0%    |
| 31-40          | 0     | 0.0%    |
| 41-50          | 2     | 5.0%    |
| 51-60          | 0     | 1.0%    |
| 61-70          | 1     | 1.0%    |
| 71-80          | 0     | 0.0%    |
| 81-90          | 0     | 0.0%    |
| Total          | 3     | 11%     |

P value | 0.722 | 0.231  
Significance | Non significant | Non significant |

Table 4: Correlation of death and rebleed with various clinical factors.

| Clinical factors          | Death | P value | Significance | Rebleed | P value | Significance |
|---------------------------|-------|---------|--------------|---------|---------|--------------|
|                           | Percentage |         |              | Percentage |         |              |
| Diabetes                  | 0.0    | 0.656   | Non significant | 2.0    | 0.588  | Non significant |
| NSAIDs                    | 0.0    | 0.633   | Non significant | 2.0    | 0.477  | Non significant |
| Antiplatelets             | 0.0    | 0.885   | Non significant | 0.0    | 0.623  | Non significant |
| Alcohol                   | 1.0    | 0.42    | Non significant | 4.0    | 0.286  | Non significant |
| Tobacco                   | 0.0    | 0.35    | Non significant | 1.0    | 0.25   | Non significant |
| History of liver disease  | 1.0    | 0.440   | Non significant | 4.0    | 0.178  | Non significant |
| Portal hypertension/     | 2.0    | 0.676   | Non significant | 5.0    | 0.073  | Non significant |
| cirrhosis                |        |         |              |         |         |              |
| Peptic ulcer disease      | 1.0    | 0.548   | Non significant | 4.0    | 0.223  | Non significant |

In this study we analyzed the correlation of mortality and rebleed with different variables using Chi-square test/ Fisher’s exact test as shown in Table 3&4.

However correlation of mortality with age, comorbidities like diabetes and liver disease was not found to be statistically significant. Also correlation between mortality and etiologic factors such as NSAIDs/Antiplatelets use, peptic ulcer disease and cirrhosis with portal hypertension was not significant. Similarly no correlation was found between rebleed and age, NSAIDs, antiplatelets use, alcohol intake, smoking and tobacco consumption. Correlation between rebleed and history of liver disease, cirrhosis with portal hypertension and peptic ulcer disease was also statistically insignificant. However we found strong correlation between rebleed and death (Table 5).
**Table 5: Correlation of rebleed and mortality.**

| Death | Rebleed Number | Percentage |
|-------|----------------|------------|
| Yes   | 3              | 3.0        |
| No    | 8              | 8.0        |
| Total | 11             | 11.0       |
| P value | 0.001       | Highly significant |

**DISCUSSION**

In our study majority of the patients (56%) were in the age group of 41-60 years and the mean age came out to be 48.98±14.50 years. Previously done studies from India have shown similar age profile of the patients. A study done by Kumar P et al reported mean age of 47.03 years. In another study by Deep Anand et al, mean age of patients were 49±14.26 years. The mean age of our study was also comparable to the studies done by Jain, Dewan and Prasad. However a study done in UK by Hearnshaw et al reported much higher mean age of 64.4 years. Majority of our patients were males with male to female ratio being 2.57:1 and similar male preponderance was seen in previous studies conducted in India and abroad possibly due the higher prevalence of risk factors like smoking and alcohol consumption among males.

In the present study hematemesis was observed in 79% of the patients and 81% had melena as the presenting complaint. Majority of the patients had both hematemesis and melena as the presenting complaint as reported in study by Anand et al and Mahajan et al. Variations in presentation among the cases of upper GI hemorrhage in the present study compared to other studies may be explained by the fact that hematemesis and melena are dependent upon the rate, amount and site of bleeding. Duodenal ulcer is likely to be present with melena more frequently than hematemesis while a bleeding gastric ulcer or esophageal varices patient may present with hematemesis more frequently than melena.

In our study 54% patients reported history of liver disease. A similar incidence was obtained in a study by Gado et al with 50% of the patients having history of liver disease. In other studies lower incidence was seen. In our study rebleeding within 15 days of the initial presentation was found in 11.9%, 13% and 16.7% of the patients. A study by Anand et al showed history of regular alcohol intake was present in 49% of the patients. A study from Sikkim showed that 87% of the patients had history of alcohol consumption. A similar study conducted by Anand et al showed history of alcohol consumption in 53.5% patients. As mentioned earlier there is increased intake of alcohol in this part of the country. According to Global status report on alcohol and health 2018 by WHO, alcohol per capita consumption has increased in India from 4.3 liters in 2010 to 5.7 liters in 2016.

In our study varices were found in 67% of the patients followed by portal hypertensive gastropathy (21%). In 16% of the patients duodenal ulcer(s) were found and gastric ulcer(s) were found in 7% of the patients. Gastric varices, duodenitis and stomach cancer each constituted 5% of the patients. Esophagitis was found in 6% of the patients and gastritis in 4%. Dieulafoy lesion, Mallory weiss tear and oesophagus cancer each constituted 1% of the patients. In 3% of the patients on endoscopy normal study was obtained. No patient had gastric antral vascular ectasia (GAVE). In a study conducted by Anand D et al the most common cause of UGI bleed was portal hypertension related (esophageal and gastric varices) seen in 56.14% of patients, peptic ulcer related bleed was seen in 14.91% patients, gastric erosions were responsible for bleed in 12.28% patients, Mallory–Weiss tear was seen in 8.77% cases, gastric malignancy accounted for 4.38% of cases, Dieulafoy’s lesion was responsible for bleed in 1.75% cases. A study conducted by Jyoti Jain et al in Central India out of 118 patients who underwent endoscopy 47.4% had esophageal varices, 27.1% had portal hypertensive gastropathy, 14.4% had gastric erosions, 5.9% each had duodenal ulcers and esophagitis, 5% had gastric ulcer disease, 4.2% each had Mallory Weiss tear and had gastric malignancy, 1.7% had esophageal malignancy and 16.1% had normal endoscopic findings. In our study, we had more than half of patients with portal hypertension related bleed secondary to cirrhosis of the liver, which are sicker than patients with other causes of GI bleed. Our being a tertiary referral center, many of these sick patients are referred to our center for evaluation and management therefore higher percentage of variceal bleed may be a referral bias in this study. Also incidence of alcohol intake and Hepatitis C is more in this part of the country. Normal endoscopic findings in 3% of the patients can be explained due to delay in endoscopy and minor mucosal lesions are well known to heal quickly and so the time interval between the bleeding episode and endoscopy influences endoscopic diagnosis.

In our study rebleeding within 15 days of the initial presentation was found in 11% of the patients (Figure 2). Of them 5 had varices on UGIE, 4 had Peptic ulcer, 1 each had Mallory weiss tear and stomach cancer. Studies done by Prasad et al, Hearnshaw et al and Minakari et al showed rebleeding in 11.9%, 13% and 16.7% of the patients respectively. However a study from 21
Tanzania\textsuperscript{22} and by Gado et al reported rebleeding in 3.3% and 6% respectively.\textsuperscript{20}

Death within 15 days of the initial presentation was found in 3% of the patients (Figure 2). All were in hospital deaths. Variability in death rate was observed in different studies. Indian studies reported death as 8.6%, 21%, 2.8% and 5.8%.\textsuperscript{13,16,17,18,19} The low death rate as compared to the other studies can be due to timely therapeutic endoscopy, effective resuscitation and exclusion of unstable patients.\textsuperscript{13,16,17,20,22} Also it can be attributed to low sample size of the study.

In our study we found no correlation between mortality and rebleeding with age, co morbidities (diabetes and liver disease), NSAIDs use, peptic ulcer disease and cirrhosis (Table 3 &4). This is in contrast to the various studies which showed a significant association between the variables. A study done by Prasad et al found factor associated with recurrent bleeding and mortality was chronic liver disease.\textsuperscript{16} Similarly Anand D et al concluded that majority of mortality was seen in portal hypertension related bleeding.\textsuperscript{13} A UK study found that mortality was highest in those with variceal bleeding (15%).\textsuperscript{17} A study done by Minakari et al found that rebleeding (present in 16.5% of patients), was found to be more frequent in patients with older age, history of taking NSAIDs and smoking, presence of comorbidities and esophageal varices.\textsuperscript{21} They found that mortality was also higher in the same group of patients that were seen to have a higher tendency for rebleeding. A Tanzanian study showed that the mortality rate of was significantly higher in patients with variceal bleeding, hepatic decompensation, comorbidities, malignancy, age>60 years.\textsuperscript{22} Lack of correlation in our study can be attributed to the wide spread use of vasoconstrictors and small sample size.

However we found significant correlation between rebleeding and death (Table 4). Out of 11 patients who rebled in our study, 3 patients died during admission period. This fact was also observed in other studies. In a study done by Anand et al it was observed that increased mortality rate was seen in the patients who rebled during the same admission.\textsuperscript{13} A similar study from Nepal reported rebleeding in 5 patients after 24 hours of performing UGIE out of which 4 patients expired.\textsuperscript{15} Hearnshaw et al reported rebleed in 13% of the patients and 27% of those patients died.\textsuperscript{17} We recognize the limitations of the present study. The most important of them being that sample size though adequate for detection of endoscopic lesions, was inadequate for the subgroup analysis. The present study was a single center study and hence not reflects the wider population.

**CONCLUSION**

Portal hypertension is the most common cause of upper gastrointestinal bleeding in this region. There is strong correlation between rebleeding and death. However there is no correlation between age, history of liver disease, diabetes, NSAIDs use, peptic ulcer disease and presence of cirrhosis with rebleed or mortality. Mortality in patients with UGI bleed is low and could be due to small sample size and exclusion of very sick patients.

**Funding: No funding sources**

**Conflict of interest: None declared**

**Ethical approval: The study was approved by the Institutional Ethics Committee**

**REFERENCES**

1. Jutabha R, Jensen DM. Acute upper gastrointestinal bleeding. In: Friedman SL, McQuaid KR, Grendell JH, eds. Current diagnosis & treatment in gastroenterology. 2\textsuperscript{nd} ed. 2003:53.

2. Rockall TA, Logen RF, Devlin HB, Northfield TC. Incidence of and mortality from acute gastrointestinal hemorrhage in the United Kingdom. Steering Committee & members of National Audit of Acute Upper Gastrointestinal hemorrhage. Br Med J. 1995;311:222.

3. Vreeburg EM, Slot P, De Buijne JW, Bartelsman JF, Rauws EA, Tytgat GN. Acute upper gastrointestinal bleeding in the Amsterdam area: Incidence, diagnosis, and clinical outcome. Am J Gastroenterol 1997;92:236.

4. Tijjani BM, Borodo MM, Samaila AA. Endoscopic findings in patients with upper gastrointestinal bleeding in Kano, North-Western Nigeria. Niger Hosp Pract. 2009;4:43-5.

5. Atchison JW, Herndon CM, Rusie E. NSAIDs for musculoskeletal pain management: current perspectives and novel strategies to improve safety. J Manag Care Pharm. 2013;19(Suppl A):1-19.

6. Rudler M, Rousseau G, Benosman H, Massard J, Deforges L, Lebray P, et al. Peptic ulcer bleeding in patients with or without cirrhosis: different diseases but the same prognosis? Aliment Pharmacol Ther. 2012;36:166-72.

7. Carbonell N, Pauwels A, Serfaty L, Fourdan O, Lévy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology. 2004;40:652-9.

8. Merli M, Nicolini G, Angeloni S, Rinaldi V, De Santis A, Merkel C, et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol. 2003;38:266-72.

9. Jaskolka JD, Binkhamis S, Prabhudesai V, Chawla TP. Acute gastrointestinal hemorrhage: Radiologic diagnosis and management. Can Assoc Radiol J. 2013;64:90-100.

10. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut. 1996;38:316–21.

11. Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, et al. International consensus recommendations on the management of patients...
with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010;152:101–13.
12. Panigrahi PK, Mohanty SS. A study on endoscopic evaluation of upper gastrointestinal bleeding. J Evid Based Med Healthc. 2016;3(27):1245-52.
13. Anand D, Gupta R, Dhar M, Ahuja V. Clinical and endoscopic profile of patients with upper gastrointestinal bleeding at tertiary care center of North India. J Digestive Endoscopy. 2014;5(04):139-43.
14. Jain J, Rawool A, Banait S, Maliye C. Clinical and endoscopic profile of the patients with upper gastrointestinal bleeding in central rural India: A hospital based cross-sectional study. J Mahatma Gandhi Inst Med Sci. 2018;23:13-8.
15. Dewan KR, Patowary BS, Bhattarai S. A Study of Clinical and Endoscopic Profile of Acute Upper Gastrointestinal Bleeding. Kathmandu Univ Med J. 2014;45(1):21-25.
16. Prasad NR, Ali SM, Ganapathy V, Sreenath GS, Kumar SS. Acute upper gastrointestinal bleeding in a tertiary care hospital in South India-Have we Improved the outcomes? Trop Gastroenterol. 2017;37:168-76.
17. Hearnshaw SA, Logan RF, Lowe D et al. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut. 2011;60:1327-35.
18. Limboo LB, Dhakal M, Dhakal OP. Clinical presentation, etiology and outcome of upper gastrointestinal bleed from a tertiary care hospital of east sikkim: an observational study. JEMDS. 2013;2(20):3568-77.
19. Mahajan P, Chandial VS. Etiological and endoscopic profile of middle aged and elderly patients with upper gastrointestinal bleeding in a Tertiary Care Hospital in North India: A retrospective analysis. J Mid-life Heal. 2017;8:137-41.
20. Gado AS, Ebeid BA, Abdelmohsen AM, Axon AT. Clinical outcome of acute upper gastrointestinal hemorrhage among patients admitted to a government hospital in Egypt. Saudi J Gastroenterol. J Saudi Gastroenterol Association. 2012;18(1):34.
21. Minakari M, Badihian S, Jalalpour P, Sebghatollahi V. Etiology and outcome in patients with upper gastrointestinal bleeding: Study on 4747 patients in the central region of Iran. J Gastroenterol Hepatol. 2017;32(4):789-96.
22. Jaka H, Koy M, Liwa A, Kabangila R, Mirambo M, Scheppach W, et al. A fibreoptic endoscopic study of upper gastrointestinal bleeding at Bugando Medical Centre in northwestern Tanzania: a retrospective review of 240 cases. BMC Research notes. 2012;5(1):200.
23. Alcoholism in Asia, The GLOBE, GAPA Bangkok consultation special issue 4. 2001-02.
24. Sood A, Sarin SK, Midha V, Hissar S, Sood N, Bansal P, et al. Prevalence of hepatitis C virus in a selected geographical area of northern India: A population based survey. Indian J Gastroenterol. 2012;31:232-6.
25. Prasad R. Alcohol use on the rise in India. Lancet. 2009;373:17-8.
26. Rathod JB, Shah DK, Yagnik BD, Yagnik VD. Upper gastrointestinal bleeding: audit of a single center experience in Western India. Clinics and practice. 2011;1(4).

Cite this article as: Kumar A, Kasturi U, Singh A, Kaur D. Endoscopic profile and clinical outcome of patients presenting with upper gastrointestinal bleeding. Int J Adv Med 2020;7:1355-60.